Suppl. Tab. 1. Characteristics of AML cell lines.

Cell line	FAB classification	Genetics
NB4	FAB M3	t(15;17) (q22;q11-12)
MV4-11	FAB M5	t(4;11)(q21;q23) FLT3-ITD mutation MLL-AF4 fusion
Molm13	FAB M5a	FLT3-ITD mutation MLL-AF9 fusion ins(11;9)(q23;p22p23)
MonoMac6	FAB M5	t(9;11)(p22;q23) MLL-AF9 fusion
OCI-AML3	FAB M4	NPM1-gene-mutation (Type A) DNMT3a R882C mutation

Suppl. Tab. 2. Synergistic induction of apoptosis by BV6 and demethylating agents in AML.

Cell line	BV6 + 5AC	BV6 + 5AC	BV6 + DAC	BV6 + DAC
	CI	***fa (%)***	***CI***	***fa (%)***
MV4-11	0.094	37.3	0.150	49.9
NB4	0.233	50.9	0.254	67.7
Molm13	0.271	56.6	0.161	64.3
MonoMac6	0.105	56.8	0.019	49.7
OCI-AML3	0.436	68	1.113	11.3

AML cell lines were treated for 72 hours with BV6 and/or 5AC or DAC as indicated in the figure legend of Fig. 1. Apoptosis was determined by forward/side scatter analysis and flow cytometry. Combination index (CI) and fraction affected (fa) were calculated by CalcuSyn software as described in Materials and Methods. CI values and fraction affected are indicated for the following concentrations: MV4-11: 300 nM 5AC/100 nM BV6, 50 nM DAC/100 nM BV6; NB4: 300 nM 5AC/600 nM BV6, 30 nM DAC/600 nM BV6; Molm13: 300 nM 5AC/100 nM BV6, 50 nM DAC/100 nM BV6; MonoMac6: 600 nM 5AC/3 µM BV6, 300 nM DAC/3 µM BV6; OCI-AML3: 100 µM 5-AC/2 µM BV6, 6 µM DAC, 2 µM BV6. CI <0.9 indicates synergism, 0.9-1.1 additivity and >1.1 antagonism.

Suppl. Fig. 1


MV4-11
NB4
cell death (%)
100
90
80
70
60
50
40
30
20
10
0
Enbrel - + - +
TNFα+BV6 - - + +

Supplementary Figure legend

Supplementary Fig. 1. Enbrel blocks BV6/TNFα-induced cell death.

MV4-11 and NB4 cells were treated for 48 hours with BV6 (MV4-11: 600 nM BV6, NB4: 100 nM BV6) and/or 30 ng/ml TNFα in the presence or absence of 100 μg/ml Enbrel. Cell death was determined by forward/side scatter analysis. Mean and SD of three experiments performed in triplicate are shown.